ABSTRACT
Objective To investigate the influencing factors for the psychological burden of depressive patients' caregivers. Methods We enrolled the chief caregivers of depressive patients who were hospitalized in Sir Run Run Shaw Hospital as our subjects. We investigated them by Caregiver Burden Inventory, Social Support Revalued Scale (SSRS) , Hamilton Depression Scale (HAMD) and Suicide Risk Assessment Scale, and learned influencing factors for the psychological burden of these caregivers by multiple linear regression analysis. Results We totally enrolled 101 subjects and collected 96 questionnaires (95.04%) . The 96 respondents scored (24.88±12.94) points in the psychological burden and 54 of which scored more than 20 points, accounted for 56.25%. The positive rate of mental pressure was 65.63%, which was the lowest; the positive rate of social burden was 93.75%, which was the highest. Multiple linear regression analysis showed that the objective support (β=-1.856, P=0.002), subjective support (β=0.526, P=0.008) and high suicidal score of depressive patients (β=0.290, P=0.048) were the influencing factors for the psychological burden of depressive patients' caregivers. Conclusion More than half of the caregivers have psychological burden, which is associated with objective support, subjective support and high suicidal score of depressive patients.
ABSTRACT
Lotus leaf (LL) is one of the traditional Chinese herbs which can be used for both pharmaceutical and food application, and it posses lipid regulating efficacy. To observe the effect of LL on experimental nonalcoholic fatty liver disease (NAFLD) and its potential mechanism, a NAFLD model was established by feeding SD rat with high-fat and high-glucose diet. LL was administrated to rats in experiment group at the same time. AST,ALT,Cr,BUN,GLU levels in serum were determined by automatic biochemical analyser and TNF-α,IL-6,INS,ADPN,LEP and liver NF-κB,TGF-β1 levels were determined by ELISA according to the specification of the kits. HE staining was applied for histopathological examination and RT-PCR,Western blot was applied for AdipoR2 mRNA and protein expression．Results have shown that LL could significantly decrease ALT,AST,IL-6 level in serum and NF-κB,TGF-β1 level in liver,promote adiponectin content in serum and AdipoR2 protein expression in liver and could alleviate hepatocyte lipid degeneration. These results indicating that LL has protective effect for NAFLD induced by high-fat and high-glucose diet via promoting AdipoR2 expression, improving insulin resistance and inhibiting inflammatory reaction.
ABSTRACT
<p><b>OBJECTIVE</b>To study the types and emergence time of YMDD motif mutation in hepatitis B virus (HBV) polymerase gene during lamivudine treatment.</p><p><b>METHODS</b>The serum samples were collected from 33 patients with HBV DNA rebounding and 2 non-responders after at least one year lamivudine treatment. HBV polymerase gene was amplificated by PCR, then the products were detected by restriction fragment length polymorphism (RFLP) and by direct sequence analysis.</p><p><b>RESULTS</b>The variants with YMDD mutation were 14 out of the 35 patients. Mutation patterns detected in these patients included four YIDD, six YVDD, three YI/VDD and one YI/MDD. The mean emergence time of YMDD variants was 11.07+/-3.65 months after the treatment, and the earliest one and the latest one occurred 5 months and 17 months after the treatment respectively. The emergence times of YIDD, YVDD, YI/VDD were (10.00 +/- 1.41) months, (11.67 +/- 4.41) months and (13.33 +/- 3.31) months respectively, which had no statistical significance (F = 0.543, P < 0.05). Three patients treated with lamivudine 200 mg every day after the mutation were followed up for 6 months, whose HBV variants had not vanished.</p><p><b>CONCLUSIONS</b>There are many kinds of HBV variants after lamivudine treatment, including YIDD, YVDD, YI/VDD and YI/MDD. The emergence time of variants is quite variable between different types and the mean time is (11.07 +/- 3.65) months after treatment, and there is no relationship between the type of YMDD mutation and the time of lamivudine administration.</p>
Subject(s)
Adolescent , Adult , Aged , Child , Female , Humans , Male , Middle Aged , Amino Acid Motifs , Genetics , Cloning, Molecular , DNA, Viral , Genetics , Drug Resistance, Viral , Genetics , Gene Products, pol , Genetics , Hepatitis B virus , Genetics , Hepatitis B, Chronic , Drug Therapy , Virology , Lamivudine , Pharmacology , Therapeutic Uses , Mutation , RNA-Directed DNA Polymerase , Genetics , Time FactorsABSTRACT
<p><b>OBJECTIVE</b>To observe the distribution of HBV variants resistant to lamivudine and their relation to clinical manifestations of chronic hepatitis.</p><p><b>METHODS</b>Using direct sequencing, YMDD (tyrosine-methionine-aspartate-aspartate) variants in patients with chronic HBV were detected before and during treatment with lamivudine. A statistical analysis of the distribution of HBV strains resistant to lamivudine was performed.</p><p><b>RESULT</b>Four variant strains existed in patients before lamivudine treatment, 128 variant resistant strains were noted after 6 mouths of lamivudine treatment including 42 YVDD (valine) variants, 20 YIDD (isoleusine) variants and 66 non-YMDD variants. According to the hepatitis severity, 8 patients were mild, 108 moderate and 12 severe. Viral loading was higher and clinical types were more severe in no-YMDD variants.</p><p><b>CONCLUSION</b>Variant strains including strains resistant to lamivudine exist naturally before lamivudine treatment, but lamivudine-resistant ones become more dominant after treatment. Liver inflammation is more severe in non-YMDD group.</p>